| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.09 | 0.007 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.008 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.008 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.094 | 0.008 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.009 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.009 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.079 | 0.009 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.092 | 0.009 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.009 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | -0.092 | 0.009 |